The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Srindhi Fine Chemicals LLP
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Novelix Pharmaceuticals Ltd's promoter group has been allotted 9,50,000 equity shares on 29 May 2026 via conversion of warrants issued under a preferential allotment. Srinidhi Fine-Chemicals LLP (Promoter) received 8,00,000 shares, while Narahari Belide (Promoter Group) received 1,50,000 shares. Post-allotment, Srinidhi Fine-Chemicals LLP's holding stands at 79,02,000 shares (33.07% of total equity, 36.68% on a diluted basis), and Narahari Belide's holding is 8,00,000 shares (3.35% of total, 4.40% diluted). The company's total equity capital has expanded from Rs. 21.09 crore (2,10,85,000 shares) to Rs. 23.90 crore (2,38,95,000 shares), with 26,50,000 promoter warrants still outstanding. Combined promoter group holding is 36.42% of total equity and 41.08% on a fully diluted basis.
This is a positive signal of promoter confidence, as the promoter group is converting warrants into actual equity rather than letting them lapse, which increases their skin in the game. The combined promoter holding remains comfortably below 50%, so there is no change of control or takeover implications for public shareholders.